| Oct 31 |
Zymeworks GAAP EPS of -$0.39 in-line, revenue of $16M misses by $1.85M
|
| Oct 31 |
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
|
| Oct 30 |
Zymeworks Q3 2024 Earnings Preview
|
| Oct 29 |
Zymeworks Announces Participation in Upcoming Investor Conferences
|
| Oct 25 |
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
|
| Oct 21 |
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
|
| Oct 10 |
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
|
| Sep 27 |
Zymeworks Approaching A Moment Of Truth With Zanidatamab
|
| Sep 18 |
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
|
| Sep 3 |
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
|
